Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer : insights from the randomized SweBCG91RT trial
Background/Aim: The TGF-β pathway can influence breast cancer progression and therapy efficacy, exhibiting both pro- and anti-tumoral effects. This study examined the impact of active TGF-β signaling on recurrence and radiotherapy (RT) benefit in early-stage breast cancer, using nuclear phosphorylated Smad2 (pSMAD2) as a marker for pathway activation. Methods: Tissue-microarrays from 1178 stage I-
